Ramucirumab

For research use only. Not for therapeutic Use.

  • Cancer Immunotherapy,
  • CAT Number: I018810
  • CAS Number: 947687-13-0
  • Molecular Formula: C6374H9864N1692O1996S46
  • Molecular Weight: 143609.63
  • Purity: ≥95%
Inquiry Now

Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor[1][2].
Ramucirumab (10 μg/mL) impedes both VEGF- and tumor-driven cord formation[3].?
Ramucirumab does not cross react with mouse VEGFR2[3].


Catalog Number I018810
CAS Number 947687-13-0
Molecular Formula C6374H9864N1692O1996S46
Purity ≥95%
Reference

[1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53.
[Content Brief]

[2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5.
[Content Brief]

[3]. Lowery CD, et al. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget. 2019 Sep 17;10(53):5523-5533.
[Content Brief]

Request a Quote